Candida albicans yeast-to-hyphal transition (YHT)

The Candida albicans yeast-to-hyphal transition is a fundamental morphogenetic switch that allows this opportunistic fungal pathogen to alternate between a commensal yeast form (blastospore) and an invasive filamentous form (hypha or mycelium). This transition is triggered by specific host environmental cues, including body temperature (37°C), neutral pH, and the presence of serum or carbon dioxide, which activate complex signaling networks like the Ras1-cAMP-PKA and mitogen-activated protein kinase (MAPK) pathways [3, 5, 12]. The formation of hyphae is a critical virulence factor, as it facilitates the penetration of host mucosal tissues, enables escape from phagocytic immune cells, and contributes to the structural complexity and resistance of fungal biofilms [1, 10, 11]. Therapeutically, targeting this transformation is a key strategy in the development of anti-virulence agents, which aim to attenuate the pathogen's ability to cause disease without necessarily killing the fungus. This approach may reduce selective pressure for drug resistance compared to traditional fungicidal treatments like azoles or polyenes [4, 9]. Various small molecules and natural products, such as the quorum-sensing molecule farnesol and the antimicrobial peptide nisin Z, have been shown to inhibit this morphological switch by interfering with signaling cascades or disrupting the cellular machinery required for polarized growth [6, 8, 11]. Despite its potential, the high degree of redundancy in the fungal regulatory network remains a significant challenge for achieving complete therapeutic inhibition.

Other names

Candida albicans blastospore to mycelial form transformationCandida albicans dimorphismCandida albicans morphogenesisYeast-to-mycelium conversionBudded-to-hyphal form transition

Drugs targeting this transition typically act by inhibiting key signal transduction pathways such as the Ras1-cAMP-PKA and Cek1-mediated MAPK pathways, disrupting actin cytoskeleton dynamics required for polar growth, or suppressing the activity of hypha-specific transcription factors like Efg1 and Cph1 [1, 3, 4, 10].